Karen Burns

Karen Burns has a diverse background in the pharmaceutical and biotechnology industry. Karen is currently working as a Marketing Director for the Envisia Genomic Classifier at Veracyte, Inc. Prior to this role, they worked as a BioPharma/Molecular Diagnostic Consultant at KVB Consulting. Karen also has experience as a Sr. Director of Commercial Operations at Guardant Health and as a Director of Commercial Development at Puma Biotechnology, Inc.

Before that, they served as a Sr. National Sales Director at Crescendo Bioscience, where they led the scale-up of the company's first Rheumatology Sales and Training division and successfully launched their first Multi-Biomarker Assay, Vectra DA. Karen'swork at Crescendo Bioscience led to the company's acquisition by Myriad Genetics. Karen also worked at Genomic Health, where they played a key role in launching Oncotype DX, a genomic test for early-stage breast and colon cancer. Karen led marketing efforts, collaborated with key opinion leaders, and promoted the product resulting in guideline inclusion and successful educational campaigns.

Prior to their work at Genomic Health, Karen held positions at Novartis Oncology and Alza Oncology (J&J) as a Sr. District Manager and Sr. Sales Manager respectively. Karen'sresponsibilities included leading sales teams and managing marketing efforts for various oncology products.

Overall, Karen Burns has a wealth of experience in marketing and commercial operations within the pharmaceutical and biotechnology industry, particularly in launching and promoting innovative genomic tests and leading sales teams.

Karen Burns attended the University of Tennessee, Knoxville, where they earned a Bachelor of Science degree in Business. Karen then pursued further education at Emory University - Goizueta Business School, where they earned an MBA in Business.